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The presented data were obtained from 982 consecutive patients
receiving their ﬁrst pacemaker implantation with right ventricular
(RV) lead placement between January 2008 and December 2013 at
two centers in Japan. Patients were divided into RV apical and
septal pacing groups. Data of Kaplan–Meier survival analysis and
Cox regression analysis are presented. Refer to the research article
“Implications of right ventricular septal pacing for medium-term
prognosis: propensity-matched analysis” (Mizukami et al., in
press) [1] for further interpretation and discussion.
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Fig. 1. Kaplan–Meier curves
cohort. No signiﬁcant differenubject area Clinical cardiology, cardiovascular electrophysiology
ore speciﬁc subject
areaCardiac pacingype of data Table, ﬁgures
ow data was
acquiredRetrospective review of medical recordsata format Analyzed
xperimental factors Japanese pacemaker patients
xperimental
featuresPatients were divided into septal and apical pacing groups, and the prognosis
were comparedata source location Kamogawa and Yokohama city, Japan
ata accessibility Data is with this articleD
Value of the data
 The prognostic implication of RV septal pacing remains unclear.
 Provided data provides insight on this topic from a large cohort of patients in real world situation.
 These data may serve as a benchmark for further data and studies regarding prognosis of RV septal
pacing.1. Data
The presented data were obtained from 982 consecutive patients receiving their ﬁrst pacemaker
implantation with right ventricular (RV) lead placement between January 2008 and December 2013
at two centers in Japan. Patients were divided into RV apical and septal pacing groups. Data of
Kaplan–Meier survival analysis for primary combined endpoint of all-cause death and hospitalizationfor combined primary endpoint of all-cause death and heart failure hospitalization of whole
ce was observed between the two pacing sites.
Fig. 2. Kaplan–Meier curves for all-cause death of whole cohort. No signiﬁcant difference was observed between the two
pacing sites.
Fig. 3. Kaplan–Meier curves for heart failure hospitalization of whole cohort. No signiﬁcant difference was observed between
the two pacing sites.
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due to heart failure (Fig. 3), as well as Cox regression analysis for the primary endpoint (Table 1) are
presented. Superiority of septal pacing was not observed in Kaplan–Meier survival analysis and Cox
regression analysis for the primary and secondary endpoints. Refer to [1] for further interpretation
and discussion.
Table 1
Univariate and multivariate Cox proportional regression analyses of the combined primary endpoint of all-cause death and
heart failure hospitalization in the whole cohort.
Univariate analysis Multivariate analysis
HR 95%CI P-value HR 95%CI P-value
RV septal pacing 0.76 0.56–1.05 0.095 1.35 0.90–2.04 0.149
Age 1.06 1.04–1.07 o0.001 1.02 1.00–1.05 0.060
History of diabetes mellitus 1.94 1.40–2.69 o0.001 1.27 0.82–1.99 0.287
History of atrial ﬁbrillation 1.25 1.06–1.49 0.010 1.62 1.08–2.43 0.021
History of heart failure 5.10 3.72–6.98 o0.001 2.61 1.73–3.95 o0.001
History of ischemic heart disease 2.69 1.93–3.75 o0.001 1.43 0.91–2.27 0.124
β-Blocker 1.77 1.26–2.49 0.001 0.89 0.57–1.39 0.600
Log QRS duration 2.71 1.36–5.41 0.005 1.95 0.76–4.96 0.164
Hemoglobin 0.73 0.67–0.79 o0.001 0.96 0.85–1.07 0.431
Log estimated GFR 0.19 0.13–0.28 o0.001 0.34 0.16–0.71 0.004
Log BNP 1.88 1.60–2.21 o0.001 1.31 1.05–1.64 0.019
Left ventricular EF 0.95 0.94–0.97 o0.001 0.98 0.96–0.99 0.003
RV, right ventricular; GFR, glomerular ﬁltration rate; EF, ejection fraction; HR, hazard ratio; CI, conﬁdence interval.
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We retrospectively included 982 consecutive patients receiving their ﬁrst pacemaker implantation
with RV lead placement between January 2008 and December 2013 at two centers in Japan (Kameda
Medical Center and Yokohama Rosai Hospital; 51.4% male, age 76.1710.6 years, 64.3% septal pacing).
The indications for pacemaker implantation were decided according to the guidelines of the Japanese
Circulation Society [2]. The target site of RV lead placement was decided by the caring physician on
the bases of patient background and operator preference. The location of the RV lead and was
assessed at the time of implantation by right anterior oblique and left anterior oblique ﬂuoroscopic
projections, as well as paced QRS morphology during implantation using the methods reported
previously [3], and was followed-up by biplane chest radiography and 12-lead ECG after implantation.
RV outﬂow tract pacing was included in the RV septal pacing group.
The primary endpoint was a combination of all-cause death and hospitalization due to heart
failure. The secondary endpoints included the individual components of the primary endpoint.
Data at the time of implantation procedure were collected, including age, sex, diagnosis for
implantation (AV block, sick sinus syndrome [SSS], or others), past history (hypertension, hyperlipi-
demia, diabetes mellitus, heart failure, atrial ﬁbrillation, and ischemic heart disease), medications
(beta-blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers, and calcium
channel blockers), ECG parameters (QRS interval, presence of complete left bundle branch block
[CLBBB]), laboratory parameters (hemoglobin, estimated glomerular ﬁltration rate [eGFR], and B-type
natriuretic peptide [BNP]), and left ventricular ejection fraction (LVEF) on transthoracic echocardio-
graphy. The diagnosis of AV block included any degree of AV block with indication for pacemaker
implantation. Hypertension, hyperlipidemia, and diabetes mellitus were scored based on the previous
diagnosis and initiation for therapy. Heart failure, atrial ﬁbrillation, and ischemic heart disease were
scored based on previous history. The Modiﬁcation of Diet in Renal Disease (MDRD) study equation
with Japanese coefﬁcient was used to calculate eGFR. This new Japanese equation is currently
recommended by the Japanese Society of Nephrology for accuracy in the Japanese population [4].
Data regarding outcome were obtained by a single investigator who was unaware of the patients'
information, including RV pacing site.
“Time 0” for survival analyses was the date of pacemaker implantation. Comparison of the
probability of freedom from the prognostic binary endpoints between groups was performed by
Kaplan–Meier survival analysis with estimation of the hazard ratio from a Cox regression model.
Univariate and multivariate Cox regression analyses were also performed to determine the prognostic
implications of each variable, including RV septal pacing, on the endpoints. Variables with Po0.1 on
A. Mizukami et al. / Data in Brief 8 (2016) 1303–1307 1307univariate analysis were entered into multivariate analysis. Logarithmic transformations of the
variables without a normal distribution were used for Cox regression analysis. The estimates of the
parameters were given with their 95% conﬁdence intervals. All P-values reported are 2-sided, and
Po0.05 was considered statistically signiﬁcant. All statistical analyses were performed with R (The R
Foundation for Statistical Computing, Vienna, Austria, version 3.1.1).Acknowledgments
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